SCHEMBL17015890

SCHEMBL17015890

c1ccc(-c2cc3ccc4c5ccccc5n(-c5cccc(-c6ccc7c(ccc8ccccc87)c6)c5)c4c3n2-c2ccccc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ HSD17B1 P14061 3/20 0.34
▸ HSD17B2 P37059 3/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2B6 P20813 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ KMT2A Q03164 4/20 0.33
▸ HAO1 Q9UJM8 1/20 0.33
▸ PDPK1 O15530 5/20 0.33
▸ APP P05067 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ ESR1 P03372 1/20 0.32
▸ ESR2 Q92731 1/20 0.32
▸ IL1R1 P14778 1/20 0.32
▸ CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17015888 0.94 L3MBTL1 (0.39) L3MBTL1KDM4EATMKMT2AHAO1
SCHEMBL17015900 0.93 L3MBTL1 (0.38) L3MBTL1KDM4EATMHSD17B1HSD17B2
SCHEMBL17015889 0.93 L3MBTL1 (0.41) L3MBTL1KDM4EATMCYP2C9KMT2A
SCHEMBL17015886 0.91 L3MBTL1 (0.40) L3MBTL1KDM4EATMHSD17B1HSD17B2
SCHEMBL17015893 0.90 L3MBTL1 (0.37) L3MBTL1KDM4EATMKMT2AHAO1
SCHEMBL17015887 0.90 L3MBTL1 (0.39) L3MBTL1KDM4EATMKMT2AHAO1
SCHEMBL17015809 0.89 KDM4E (0.38) L3MBTL1KDM4EATMHSD17B1HSD17B2
SCHEMBL17015903 0.89 L3MBTL1 (0.38) L3MBTL1KDM4EATMHSD17B1HSD17B2
SCHEMBL17015945 0.88 KDM4E (0.47) L3MBTL1KDM4EATMCYP2C9KMT2A
SCHEMBL17015950 0.87 L3MBTL1 (0.42) L3MBTL1KDM4EATMKMT2AHAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 — — US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 — — US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 — — US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 L3MBTL1 533/4885KDM4E 1286/4885ATM 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback